NCT00438737Unknown2 期
Randomized Phase II Trial Evaluating the Feasibility and Tolerance of the Combination of FOLFOX With Cetuximab and the Combination of FOLFOX With Cetuximab and Bevacizumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2007年1月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 100
- 试验地点
- 2
- 主要终点
- Response rate (preoperative response rate)
研究概览
简要总结
RATIONALE: Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.Drugs used in chemotherapy, such as leucovorin, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with combination chemotherapy and bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This randomized phase II trial is studying the side effects and how well giving cetuximab together with leucovorin, oxaliplatin, and fluorouracil works with or without bevacizumab in treating patients with resectable liver metastases from colorectal cancer.
详细描述
OBJECTIVES:
- Compare the safety and activity of neoadjuvant and adjuvant cetuximab, leucovorin calcium, oxaliplatin, and fluorouracil with vs without bevacizumab in patients with resectable liver metastases secondary to colorectal cancer.
OUTLINE: This is an open-label, randomized, multicenter study. Patient are stratified according to participating center and planned liver resection (major [≥ 3 segments] vs minor [< 3 segments]). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV over 46 hours (FOLFOX) beginning on day 1. Patients also receive cetuximab IV over 1-2 hours on days 1 and 8. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Between 3-5 weeks after completion of FOLFOX and cetuximab, patients undergo liver resection. Beginning between 4-8 weeks after surgery, patients receive another 6 courses of FOLFOX and cetuximab as in neoadjuvant therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Diagnosis of metastatic colorectal cancer, meeting all of the following criteria:
- •Metachronous or synchronous liver metastases
- •Metastases potentially completely resectable
- •No requirement for resection combined with cryotherapy or radiofrequency ablation
- •Must have undergone complete resection (R0) of the primary tumor within the past 4 weeks
- •Measurable liver metastases
- •No evidence of extrahepatic disease
- •1 or 2 resectable lung metastases allowed
- •PATIENT CHARACTERISTICS:
- •WHO performance status 0-1
- •Absolute neutrophil count > 1,500/mm³
- •Platelet count > 100,000/mm³
- •Hemoglobin > 9 g/dL
- •WBC > 3,000/mm³
- •Creatinine < 1.5 times upper limit of normal (ULN)
- •Bilirubin < 1.5 times ULN
- •AST and ALT < 5 times ULN
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No significant proteinuria (i.e., protein > 500 mg/24-hour urine collection)
- •No known allergy to any of the study drugs (including excipients) or any related compound, including hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
- •No bleeding diathesis or coagulopathy
- •No peripheral neuropathy > grade 1
- •No serious nonhealing wound, ulcer, or bone fracture
- •No clinically significant cardiovascular disease, including any of the following:
- •Uncontrolled hypertension
- •New York Heart Association class II-IV congestive heart failure
- •Unstable angina pectoris within the past 12 months
- •Peripheral vascular disease ≥ grade 2
- •Serious cardiac arrhythmia requiring medication
- •Myocardial infarction within the past 12 months
- •Cerebrovascular accident or transient ischemic attack within the past 12 months
- •No symptomatic diverticulitis or known gastroduodenal ulceration
- •No significant traumatic injury within the past 4 weeks
- •No known alcohol or drug abuse
- •No psychological, familial, social, or geographical condition that would preclude study compliance
- •No other significant disease that would preclude study participation
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •No prior chemotherapy for metastatic disease
- •At least 1 month since prior major surgical procedure or open biopsy
- •More than 30 days since prior participation in another clinical study
- •Prior adjuvant chemotherapy for primary cancer allowed provided the following criteria are met:
- •At least 12 months since prior oxaliplatin-containing adjuvant therapy
- •No persistent neuropathy
- •No prior therapy targeting the epidermal growth factor receptor or vascular endothelial growth factor (VEGF)/VEGF receptor
- •No concurrent regular use of acetylsalicylic acid (> 325 mg/day) or other nonsteroidal anti-inflammatory drugs
- •No concurrent full-dose anticoagulation
- 另有 2 项未显示
排除标准
- 未提供
结局指标
主要结局
Response rate (preoperative response rate)
Safety (rate of perioperative safety findings)
次要结局
- Progression-free survival
- Pathological resection rate
- Overall survival
研究者
研究点 (2)
Loading locations...
相似试验
撤回
2 期
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal CancerColorectal CancerNCT00571740Alliance for Clinical Trials in Oncology
终止
2 期
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By SurgeryHead and Neck CancerNCT00646659European Organisation for Research and Treatment of Cancer - EORTC47
已完成
2 期
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal CancerColorectal CancerNCT00556413Institut du Cancer de Montpellier - Val d'Aurelle42
已完成
2 期
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By SurgeryColorectal CancerNCT00423696UNICANCER145
已完成
2 期
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the LarynxRecurrent Verrucous Carcinoma of the Oral CavitySalivary Gland Squamous Cell CarcinomaStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the NasopharynxStage IVA Salivary Gland CancerStage IVA Squamous Cell Carcinoma of the LarynxStage IVA Squamous Cell Carcinoma of the Lip and Oral CavityStage IVA Squamous Cell Carcinoma of the OropharynxStage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IVA Verrucous Carcinoma of the LarynxStage IVA Verrucous Carcinoma of the Oral CavityStage IVB Salivary Gland CancerStage IVB Squamous Cell Carcinoma of the LarynxStage IVB Squamous Cell Carcinoma of the Lip and Oral CavityStage IVB Squamous Cell Carcinoma of the OropharynxStage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IVB Verrucous Carcinoma of the LarynxStage IVB Verrucous Carcinoma of the Oral CavityStage IVC Salivary Gland CancerStage IVC Squamous Cell Carcinoma of the LarynxStage IVC Squamous Cell Carcinoma of the Lip and Oral CavityStage IVC Squamous Cell Carcinoma of the OropharynxStage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IVC Verrucous Carcinoma of the LarynxStage IVC Verrucous Carcinoma of the Oral CavityUntreated Metastatic Squamous Neck Cancer With Occult PrimaryTongue CancerNCT00939627National Cancer Institute (NCI)55